Aggressive cholesterol drugs may shrink artery plaque in young patients

NCT ID NCT05783804

Recruiting now Disease control Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether starting strong cholesterol-lowering therapy early can reverse plaque buildup in the arteries of young adults (ages 18-50) with familial hypercholesterolemia, a genetic condition causing very high cholesterol. Researchers will use CT scans to measure changes in plaque volume over time. The goal is to see if aggressive treatment can stop or even reverse artery disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lipid-lowering therapy (statins and/or other cholesterol drugs)
What this could lead to: If it works, this could show that early aggressive treatment can reverse artery plaque buildup, potentially reducing heart attack risk in young people with this genetic condition.
What could go wrong: This is a small early-phase study with only 60 participants, so results may not apply to everyone. Plaque reversal may be modest or not occur, and aggressive lipid-lowering carries risks like muscle pain or liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE PROGRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder familial hypercholesterolemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE PROGRESSION

Contacts and locations

Locations

Amsterdam UMC, location AMC
RECRUITING

Amsterdam, North Holland, 1105 AZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.